@Amgen profile picture
Amgen 🧪🔬🧬 @Amgen
Joined April 2009
  • Tweets 14,144
  • Following 967
  • Followers 118,971
4,330 Photos and videos
Ohio’s thriving manufacturing hub shows what’s possible when innovation, talent, and pro-growth tax policies align. We're proud to be part of this momentum, investing more than $1.4B in Ohio to help strengthen U.S. leadership in biotech. amgen.ly/3S2ARZd
3
6
612
NEWS: At #ADASciSessions 2026, we’re advancing the conversation around cardiometabolic care. New data reinforce the need for more integrated approaches to prevention, risk reduction, and long-term management across obesity, diabetes and cardiovascular disease. 🔗 Read more: amgen.ly/4uVXTQd $AMGN
0:16
3
4
1,007
People living with cardiometabolic conditions often face interconnected risks that can compound over time. This week at @AmDiabetesAssn’s #ADASciSessions, we’re helping advance the conversation around a more integrated approach to obesity, diabetes and cardiovascular disease and long-term management.
3
9
701
How will AI shape the future of Amgen? CEO Bob Bradway recently joined Sarah Elk and AI pioneer @AndrewYNg on @BainandCompany's Winning with AI podcast to discuss how AI is helping accelerate innovation across drug discovery, development, and manufacturing. 🎙️Watch the full podcast: amgen.ly/4vym86Z $AMGN
0:22
2
2
5
741
📢 Amgen announced the presentation of new data across rare autoimmune & inflammatory diseases at #EULAR2026. Research highlights IgG4-related disease & real-world evidence in ANCA-associated vasculitis. 🔗 Learn more: amgen.ly/4a8lyEu $AMGN
0:06
1
2
4
971
🔬 Small cell lung cancer news: Amgen’s DLL3-targeting therapy is now approved in the European Union for certain patients with extensive-stage small cell lung cancer (#SCLC). 🔗 Learn more: amgen.ly/4feYaZr
0:07
1
3
9
1,498
Cancer research doesn't stand still at Amgen. At #ASCO2026, we’re sharing new data in SCLC, colorectal cancer, prostate cancer, Ewing sarcoma & more. ➡️ Explore full abstracts: amgen.ly/43nAc7j
0:44
2
10
1,065
Amgen announced the planned retirement of EVP and CFO Peter Griffith. Thomas Dittrich will return to Amgen and succeed Griffith as CFO effective Sept. 1, 2026. “We are grateful to Peter for his leadership and lasting impact on the company,” said Chairman and CEO Robert A. Bradway. More: amgen.ly/4tOOxEm $AMGN
0:06
1
8
1,122
A major milestone in our more than $1.5 billion investment in Holly Springs, North Carolina. The final steel topping beam is now in place at Amgen’s newest advanced manufacturing facility — expanding U.S. biomanufacturing capabilities for the future. $AMGN
4
6
16
2,598
Headed to #ECO2026? Join us for our symposium and learn more about the evolving obesity treatment landscape. 🔗Learn more about our scientific approach to obesity: amgen.ly/4np5bZM
1
2
9
1,341
How do you navigate B-cell ALL at 21? After years of hospital stays & uncertainty, William is in remission. Now he’s helping other young people advocate for themselves. Read his story: amgen.ly/49pJfI3 @TheMightySite #AmgenSponsored

Redefining ‘Strength’: Living With B-All as a Young Adult

William has always been driven. Originally from Nebraska, his family moved to Indiana in his sophomore year of high school where

themighty.com
1
9
884
Amgen 🧪🔬🧬 retweeted
Jenniffer González
@Jenniffer
May 7
AMGEN continúa fortaleciendo su presencia en nuestra isla con una inversión adicional de $300 millones, impulsando la creación de empleos, el desarrollo económico y nuevas oportunidades para nuestra gente. Por más de tres décadas, esta alianza ha sido parte clave del crecimiento industrial y científico de Puerto Rico, demostrando la confianza de empresas globales en el talento puertorriqueño y en el potencial de nuestra isla.
0:42
13
13
33
2,533
Amgen is investing an additional $300M in its U.S. manufacturing network to advance production capacity, enhance next-generation technologies and support a reliable supply of medicines. Total U.S. manufacturing investments announced over the past year now reach nearly $2B. 🔗See how Amgen is leading what’s next in biotech innovation: amgen.ly/4tPfB7l $AMGN
0:05
3
9
19
3,004
Amgen reports Q1 2026 earnings: amgen.ly/4tcBhcv Safe Harbor: amgen.ly/4cYdXJc $AMGN
Amgen Reports Q1 2026 Earnings

ALT Amgen Reports Q1 2026 Earnings

1
2
6
1,027
Amgen will report Q1 2026 financial results tomorrow. Details here: amgen.ly/4vQMMsC $AMGN
0:05
3
804
Amgen will report Q1 2026 financial results on Thursday, April 30. Details here: amgen.ly/4ee1JPb $AMGN
0:05
4
906
🔬Amgen San Francisco has expanded with new small-molecule discovery labs. Powered by the DMTA cycle: Design → Make → Test → Analyze Scientists are working to accelerate discovery, designing molecules that could one day become medicines. 🎉
1:28
1
4
15
2,043
We’re excited to share positive Phase 3 data evaluating a subcutaneous administration of our treatment for Thyroid Eye Disease (TED) in people with moderate-to-severe active TED. 🔗 Read the press release to learn more: amgen.ly/4tBdnrP $AMGN
0:06
1
8
12
1,999
Amgen has published its 2025 Letter to Shareholders. 🔗amgen.ly/4v1q40t This year’s letter highlights our strong performance in 2025 and how we are advancing innovative medicines, driving scientific innovation, and investing in manufacturing to better serve patients around the world. $AMGN
2
1
8
858
📢 NEWS: Late-breaking Phase 3 data presented at @ACCinTouch’s #ACC26 support earlier intensive LDL-C lowering to reduce the risk of a first major CV event in high-risk patients without known atherosclerosis. ➡️ Read more: amgen.ly/4lSs2vO
0:07
3
5
3,081
Load more